Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Analyst Ratings
Moderate Buy
10 Buy
14 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BIIB Stock 12 Month Forecast
Average Price Target
$165.83
▲(25.68%Upside)
| Highest Price Target$224.00 | Average Price Target$165.83 | Lowest Price Target$115.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$146
Buy
10.65%
Upside
Reiterated
08/02/25
Biogen's overall stock score is driven by its solid financial foundation and positive earnings call sentiment. The company's strong new product performance offsets some of the risks associated with declining revenues. Technical indicators provide mixed signals, but the attractive valuation supports a favorable outlook.
H.C. Wainwright
$187→$194
Buy
47.03%
Upside
Reiterated
08/01/25
Needham
―
Hold
―
Reiterated
08/01/25
Truist Financial
―
Hold
―
Reiterated
08/01/25
Citi
$125→$135
Hold
2.31%
Upside
Reiterated
08/01/25
Scotiabank
$224
Buy
69.76%
Upside
Reiterated
08/01/25
William Blair
―
Buy
―
Reiterated
07/31/25
Biogen's Strong Performance and Positive Outlook Drive Buy RatingWe note this includes a one-time shipment to China of approximately $35 million. Skyclarys achieved second-quarter sales of $130 million, but the commercial focus remains on Leqembi, which has seen only modest growth relative to expectations, in our view. The legacy MS franchise also outperformed expectations this quarter, but we continue to expect genericization pressures and increased anti-CD20 utilization will erode this franchise as a growth driver for Biogen. Adjusted net income of $803 million ($5.47/share) was above our estimate of $603 million ($4.11/share) and consensus of $583 million ($4.10/share). We provide consolidated variance from our estimates in exhibit 1 on page 2 of the note.
Bank of America Securities
$143
Hold
8.37%
Upside
Reiterated
07/31/25
TD Cowen
$175
Buy
32.63%
Upside
Reiterated
07/31/25
Morgan Stanley
$146→$144
Hold
9.13%
Upside
Reiterated
07/31/25
Oppenheimer
$205
Buy
55.36%
Upside
Reiterated
07/31/25
RBC Capital
$208→$219
Buy
65.97%
Upside
Reiterated
07/31/25
Piper Sandler
$115
Hold
-12.85%
Downside
Reiterated
07/29/25
Goldman Sachs
$196
Buy
48.54%
Upside
Reiterated
07/24/25
Wedbush
$121→$129
Hold
-2.24%
Downside
Reiterated
07/17/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$146
Buy
10.65%
Upside
Reiterated
08/02/25
Biogen's overall stock score is driven by its solid financial foundation and positive earnings call sentiment. The company's strong new product performance offsets some of the risks associated with declining revenues. Technical indicators provide mixed signals, but the attractive valuation supports a favorable outlook.
H.C. Wainwright
$187→$194
Buy
47.03%
Upside
Reiterated
08/01/25
Needham
―
Hold
―
Reiterated
08/01/25
Truist Financial
―
Hold
―
Reiterated
08/01/25
Citi
$125→$135
Hold
2.31%
Upside
Reiterated
08/01/25
Scotiabank
$224
Buy
69.76%
Upside
Reiterated
08/01/25
William Blair
―
Buy
―
Reiterated
07/31/25
Biogen's Strong Performance and Positive Outlook Drive Buy RatingWe note this includes a one-time shipment to China of approximately $35 million. Skyclarys achieved second-quarter sales of $130 million, but the commercial focus remains on Leqembi, which has seen only modest growth relative to expectations, in our view. The legacy MS franchise also outperformed expectations this quarter, but we continue to expect genericization pressures and increased anti-CD20 utilization will erode this franchise as a growth driver for Biogen. Adjusted net income of $803 million ($5.47/share) was above our estimate of $603 million ($4.11/share) and consensus of $583 million ($4.10/share). We provide consolidated variance from our estimates in exhibit 1 on page 2 of the note.
Bank of America Securities
$143
Hold
8.37%
Upside
Reiterated
07/31/25
TD Cowen
$175
Buy
32.63%
Upside
Reiterated
07/31/25
Morgan Stanley
$146→$144
Hold
9.13%
Upside
Reiterated
07/31/25
Oppenheimer
$205
Buy
55.36%
Upside
Reiterated
07/31/25
RBC Capital
$208→$219
Buy
65.97%
Upside
Reiterated
07/31/25
Piper Sandler
$115
Hold
-12.85%
Downside
Reiterated
07/29/25
Goldman Sachs
$196
Buy
48.54%
Upside
Reiterated
07/24/25
Wedbush
$121→$129
Hold
-2.24%
Downside
Reiterated
07/17/25
Best Analysts Covering Biogen
1 Month
xxx
Success Rate
16/33 ratings generated profit
Average Return
+0.69%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 48.48% of your transactions generating a profit, with an average return of +0.69% per trade.
3 Months
xxx
Success Rate
18/39 ratings generated profit
Average Return
-4.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -4.01% per trade.
1 Year
Success Rate
9/33 ratings generated profit
Average Return
-11.75%
reiterated a buy rating 4 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -11.75% per trade.
2 Years
xxx
Success Rate
11/39 ratings generated profit
Average Return
-20.53%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 28.21% of your transactions generating a profit, with an average return of -20.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BIIB Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
14
13
15
16
9
Buy
8
10
15
23
19
Hold
32
28
41
38
31
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
51
71
77
59
Each month's total comprises the sum of three months' worth of ratings.
BIIB Financial Forecast
BIIB Stock Forecast FAQ
What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is 165.83.
What is BIIB’s upside potential, based on the analysts’ average price target?
Biogen has 25.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BIIB a Buy, Sell or Hold?
Biogen has a consensus rating of Moderate Buy which is based on 10 buy ratings, 14 hold ratings and 0 sell ratings.
What is Biogen’s price target?
The average price target for Biogen is 165.83. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $224.00 ,the lowest forecast is $115.00. The average price target represents 25.68% Increase from the current price of $131.95.
The highest analyst price target is $224.00 ,the lowest forecast is $115.00. The average price target represents 25.68% Increase from the current price of $131.95.
What do analysts say about Biogen?
Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.
How can I buy shares of BIIB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.